These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36643943)

  • 1. FDG PET/CT Maximum Tumor Dissemination to Predict Recurrence in Patients with Diffuse Large B-Cell Lymphoma.
    Jo JH; Chung HW; Kim SY; Lee MH; So Y
    Nucl Med Mol Imaging; 2023 Feb; 57(1):26-33. PubMed ID: 36643943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of Dmax and %ΔSUVmax of
    Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
    BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Xu HQ; Song LJ; Ding CY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1690-1700. PubMed ID: 38071047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of baseline
    Zhu L; Meng Y; Guo L; Zhao H; Shi Y; Li S; Wang A; Zhang X; Shi J; Zhu J; Xu K
    Oncol Lett; 2021 Feb; 21(2):132. PubMed ID: 33552253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting diffuse large B-cell lymphoma outcomes with lesion-to-liver maximum standardized uptake value for interim-treatment and end-of-treatment positron emission tomography-computed tomography.
    Wang L; Zhang S; Xin J
    Quant Imaging Med Surg; 2023 Oct; 13(10):6789-6800. PubMed ID: 37869355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
    Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of
    Michaud L; Bantilan K; Mauguen A; Moskowitz CH; Zelenetz AD; Schöder H
    J Nucl Med; 2023 Apr; 64(4):536-541. PubMed ID: 36549918
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Girum KB; Rebaud L; Cottereau AS; Meignan M; Clerc J; Vercellino L; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
    J Nucl Med; 2022 Dec; 63(12):1925-1932. PubMed ID: 35710733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating Outcome Prediction via Baseline, End-of-Treatment, and Delta Radiomics on PET-CT Images of Primary Mediastinal Large B-Cell Lymphoma.
    Yousefirizi F; Gowdy C; Klyuzhin IS; Sabouri M; Tonseth P; Hayden AR; Wilson D; Sehn LH; Scott DW; Steidl C; Savage KJ; Uribe CF; Rahmim A
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome.
    Wang F; Cui S; Lu L; Shao X; Yan F; Liu Y; He B; Wang J; Cao Y; Yue Y; Wang Y; Gu W
    BMC Cancer; 2023 Nov; 23(1):1165. PubMed ID: 38030989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
    Toledano MN; Vera P; Tilly H; Jardin F; Becker S
    PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL).
    Xie Y; Teng Y; Jiang C; Ding C; Zhou Z
    Jpn J Radiol; 2023 Jul; 41(7):777-786. PubMed ID: 36752954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A different perspective on PET/CT before treatment in patients with Hodgkin lymphoma: importance of volumetric and dissemination parameters.
    Aksu A; Küçüker KA; Solmaz Ş; Turgut B
    Ann Hematol; 2024 Mar; 103(3):813-822. PubMed ID: 37964021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of
    Geng H; Lian K; Zhang W
    Quant Imaging Med Surg; 2024 Jan; 14(1):325-334. PubMed ID: 38223089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective head-to-head comparison of the Lugano classification and PERCIST for FDG-PET/CT response assessment in diffuse large B-cell lymphoma.
    Nielsen NB; Gerke O; Nielsen AL; Juul-Jensen K; Larsen TS; Møller MB; Hildebrandt MG
    Clin Physiol Funct Imaging; 2024 Jan; 44(1):70-78. PubMed ID: 37501554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.
    Decazes P; Becker S; Toledano MN; Vera P; Desbordes P; Jardin F; Tilly H; Gardin I
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1672-1679. PubMed ID: 29705879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of therapeutic effect and prognostic value of
    Zhao W; Wu X; Huang S; Wang H; Fu H
    EJNMMI Res; 2024 Feb; 14(1):20. PubMed ID: 38372908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma.
    Baratto L; Wu F; Minamimoto R; Hatami N; Liang T; Sabile J; Advani RH; Mittra E
    Nucl Med Commun; 2021 Jul; 42(7):792-799. PubMed ID: 33741852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of clinical characteristics and baseline
    Huang W; Chao F; Li L; Gao Y; Qiu Y; Wang W; Gao J; Han X; Kang L
    Quant Imaging Med Surg; 2023 Dec; 13(12):8571-8586. PubMed ID: 38106313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.